Immunai raises $60M as it expands from improving immune therapies to discovering new ones, too
TechCrunch
FEBRUARY 11, 2021
Just three years after its founding, biotech startup Immunai has raised $60 million in Series A funding, bringing its total raised to over $80 million. “I hope it doesn’t sound corny, but we don’t have the luxury to move more slowly,” explained Immunai co-founder and CEO Noam Solomon in an interview.
Let's personalize your content